1. |
Tang J, Kern TS. Inflammation in diabetic retinopathy [J]. Prog Retin Eye Res, 2011, 30(5): 343-358. DOI: 10.1016/j.preteyeres.2011.05.002.
|
2. |
Miyamoto K, Oqura Y. Pathogenetic potential of leukocytes in diabetic retinopathy [J]. Semin Ophthalmol, 1999, 14(4): 233-239.
|
3. |
Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition [J]. Proc Natl Acad Sci USA, 1999, 96(19): 10836-10841.
|
4. |
Imeri F, Blanchard O, Jenni A, et al. FTY720 and two novel butterfly derivatives exert a general anti-inflammatory potential by reducing immune cell adhesion to endothelial cells through activation of S1P and phosphoinositide 3-kinase [J]. Naunyn Schmiedebergs Arch Pharmacol, 2015, 388(12):1283-1292. DOI: 10.1007/s00210-015-1159-5.
|
5. |
段惠惠, 黄建梅, 于素云, 等. STZ糖尿病大鼠视网膜病变模型的再评价 [J]. 中国比较医学杂志, 2013, 23(5): 12-18.Duan HH, Huang JM, Yu SY, et al. Revaluation of experimental animal model of diabetic retinoapthy induced by STZ rats [J]. Chin J Compar Med, 2013, 23(5): 12-18.
|
6. |
杨宏伟, 陈晓隆, 卜立敏, 等. 细胞凋亡在STZ诱导糖尿病大鼠早期视网膜病变中的作用机制 [J]. 眼科研究, 2009, 27(6): 472-476.Yang HW, Chen XL, Pu LM, et al. Mechanism of apoptosis in early diabetic retina induced by STZ in rat[J]. Chin Ophthalmic Res, 2009, 27(6): 472-476.
|
7. |
Copland DA, Liu J, Schewitz-Bowers LP, et al. Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier [J]. Am J Pathol, 2012, 180(2): 672-681. DOI: 10.1016/j.ajpath.2011.10.008.
|
8. |
Miyahara S, Kiryu J, Yamashiro K, et al. Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes [J]. Am J Pathol, 2004, 164(5): 1697-1706.
|
9. |
Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue [J]. Invest Ophthalmol Vis Sci, 2001, 42(3): 789-794.
|
10. |
Jorns A, Rath KJ,Terbish T, et al. Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation [J]. Endocrinology, 2010, 151(8): 3555-3565. DOI: 10.1210/en.2010-0202.
|
11. |
Kim JA, Berliner JA, Natarajan RD, et al. Evidence that glucose increases monocyte binding to human aortic endothelial cells [J]. Diabetes, 1994, 43(9): 1103-1107.
|
12. |
Nowak M, Wielkoszynski T, Marek B, et al. Blood serum levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy [J]. Clin Exp Med, 2008, 8(3): 159-164. DOI: 10.1007/s10238-008-0173-z.
|
13. |
Sharma S, Purohit S, Sharma A, et al. Elevated serum levels of soluble TNF receptors and adhesion molecules are associated with diabetic retinopathy in patients with type-1 diabetes [J/OL]. Mediators Inflamm, 2015, 2015:279393[2015-08-03]. http://dx.doi.org/10.1155/2015/279393. DOI: 10.1155/2015/279393.
|
14. |
Wang L, Sammani S, Moreno-Vinasco L, et al. FTY720 (s)-phosphonate preserves sphingosine 1-phosphate receptor 1 expression and exhibits superior barrier protection to FTY720 in acute lung injury [J]. Crit Care Med, 2014, 42(3): 189-199. DOI: 10.1097/CCM.0000000000000097.
|
15. |
Spampinato SF, Obermeier B, Cotleur A, et al. Sphingosine 1 phosphate at the blood brain barrier: can the modulation of S1P Receptor 1 influence the response of endothelial cells and astrocytes to inflammatory stimuli? [J/OL]. PLoS One, 2015, 10(7): 0133392[2015-07-21]. http://dx.plos.org/10.1371/journal.pone.0133392. DOI: 10.1371/journal.pone.0133392.
|
16. |
Nishihara H, Shimizu F, Sano Y, et al. Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis [J]. PLoS One, 2015, 10(3): 0121488[2015-03-16]. http://dx.plos.org/10.1371/journal.pone.0121488. DOI: 10.1371/journal.pone.0121488.
|